Aberdeen Australia Equity Fund (IAF) Trades at $6.09 After Triangle, Aduro Biotech (ADRO) Shorts Decreased By 1.98%

June 19, 2017 - By Louis Casey

Aduro Biotech Incorporated (NASDAQ:ADRO) had a decrease of 1.98% in short interest. ADRO’s SI was 6.00M shares in June as released by FINRA. Its down 1.98% from 6.12M shares previously. With 328,900 avg volume, 18 days are for Aduro Biotech Incorporated (NASDAQ:ADRO)’s short sellers to cover ADRO’s short positions. The SI to Aduro Biotech Incorporated’s float is 20.57%. It closed at $10.55 lastly. It is down 1.22% since June 19, 2016 and is uptrending. It has underperformed by 15.48% the S&P500.

Aberdeen Australia Equity Fund Inc (IAF) formed triangle with $5.54 target or 9.00% below today’s $6.09 share price. Aberdeen Australia Equity Fund Inc (IAF) has $135.61 million valuation. It closed at $6.09 lastly. It is down 3.51% since June 19, 2016 and is uptrending. It has underperformed by 13.19% the S&P500.

Aduro Biotech, Inc. is an immunotherapy company, which focuses on the discovery, development and commercialization of therapies that manage the treatment of various diseases, including cancer. The company has market cap of $741.10 million. The Company’s product candidates from its Live, Attenuated, Double-Deleted Listeria monocytogenes, Stimulator of Interferon Genes Pathway Activator, and B-select monoclonal antibody platforms are designed to stimulate and/or regulate innate and adaptive immune responses, either as single agents or in combination with conventional therapies, as well as other immunotherapies. It currently has negative earnings. The Company’s LADD technology platform is being developed as a treatment for multiple indications, including mesothelioma, ovarian, gastric, lung and prostate cancers.

Among 6 analysts covering Aduro Biotech (NASDAQ:ADRO), 3 have Buy rating, 1 Sell and 2 Hold. Therefore 50% are positive. Aduro Biotech had 10 analyst reports since August 19, 2015 according to SRatingsIntel. FBR Capital maintained it with “Outperform” rating and $22 target in Tuesday, May 17 report. The rating was downgraded by Bank of America to “Underperform” on Tuesday, March 15. The company was initiated on Wednesday, August 19 by Leerink Swann. The rating was maintained by Roth Capital on Tuesday, November 24 with “Buy”. The stock of Aduro BioTech Inc (NASDAQ:ADRO) earned “Buy” rating by Roth Capital on Tuesday, March 7. On Thursday, September 3 the stock rating was upgraded by Zacks to “Hold”. The rating was maintained by Roth Capital with “Buy” on Thursday, August 27. On Tuesday, December 1 the stock rating was downgraded by Oppenheimer to “Perform”. The company was maintained on Tuesday, November 24 by TH Capital. Oppenheimer initiated Aduro BioTech Inc (NASDAQ:ADRO) on Tuesday, October 20 with “Outperform” rating.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our daily email newsletter.



Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: